Published in J Clin Microbiol on June 06, 2007
Human malaria parasites in continuous culture. Science (1976) 59.70
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Fast emergence of Plasmodium falciparum resistance to halofantrine. Lancet (1993) 3.03
Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob Agents Chemother (2002) 3.01
A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Am J Trop Med Hyg (2001) 2.73
Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother (2006) 1.89
The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J Clin Pharm Ther (2004) 1.71
In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother (2005) 1.46
Rapid colorimetric method for testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin in liquid cultures. J Clin Microbiol (2003) 1.31
Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Trans R Soc Trop Med Hyg (2003) 1.28
Molecular epidemiology of malaria in cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am J Trop Med Hyg (2004) 1.13
Field evaluation of a novel colorimetric method--double-site enzyme-linked lactate dehydrogenase immunodetection assay--to determine drug susceptibilities of Plasmodium falciparum clinical isolates from northwestern Thailand. Antimicrob Agents Chemother (2004) 1.11
Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar J (2006) 1.06
Inoculum effect leads to overestimation of in vitro resistance for artemisinin derivatives and standard antimalarials: a Gambian field study. Parasitology (1999) 0.94
Halofantrine resistance in African countries. Lancet (1993) 0.80
[Factors affecting the in vitro microtest for drug sensitivity of Plasmodium falciparum]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2003) 0.79
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health (2006) 4.44
Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health (2006) 4.32
The threat of artemisinin-resistant malaria. N Engl J Med (2011) 4.15
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One (2013) 3.66
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother (2012) 3.12
Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother (2012) 3.01
The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med (2002) 2.79
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A (2009) 2.54
Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J (2009) 2.33
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members. Arch Intern Med (2009) 2.07
Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg (2012) 1.97
Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg (2007) 1.97
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother (2006) 1.89
Predictive factors of malaria in travelers to areas where malaria is endemic. Arch Intern Med (2002) 1.86
Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One (2010) 1.86
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother (2007) 1.85
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer (2011) 1.85
Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed (2010) 1.85
Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother (2010) 1.76
Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis (2004) 1.74
In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother (2003) 1.72
Evaluation of the intra- and inter-specific genetic variability of Plasmodium lactate dehydrogenase. Malar J (2007) 1.71
Artemisinin resistance is a clear and present danger. Trends Parasitol (2013) 1.62
Continual reassessment method for ordered groups. Biometrics (2003) 1.60
Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect (2006) 1.56
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J (2007) 1.56
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi]. Trop Med Int Health (2004) 1.56
Invasion of Africa by a single pfcrt allele of South East Asian type. Malar J (2006) 1.51
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavage. Crit Care Med (2005) 1.51
Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer (2006) 1.51
Non-parametric optimal design in dose finding studies. Biostatistics (2002) 1.51
Leukocyte activation: the link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris. Crit Care Med (2008) 1.50
Chimpanzee malaria parasites related to Plasmodium ovale in Africa. PLoS One (2009) 1.49
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
Hospitalization criteria in imported falciparum malaria. J Travel Med (2007) 1.45
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One (2007) 1.44
World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J (2007) 1.41
[Rapid detection of malaria and P. falciparum chemoresistant genotypes in Mayotte, 2001]. Presse Med (2002) 1.41
Resistance to dihydroartemisinin. Emerg Infect Dis (2006) 1.40
Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg (2005) 1.39
Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2007) 1.37
Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am J Trop Med Hyg (2007) 1.36
Combined deletions of pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test. J Clin Microbiol (2011) 1.34
Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health (2004) 1.33
Mekong malaria. II. Update of malaria, multi-drug resistance and economic development in the Mekong region of Southeast Asia. Southeast Asian J Trop Med Public Health (2003) 1.31
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics (2009) 1.31
Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern. Trans R Soc Trop Med Hyg (2006) 1.30
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis (2012) 1.29
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria. Malar J (2009) 1.29
Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother (2003) 1.24
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
A database of antimalarial drug resistance. Malar J (2006) 1.24
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J (2012) 1.23
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother (2005) 1.23
Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg (2011) 1.23
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2010) 1.22
Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ (2002) 1.21
Current status of artemisinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in Bangladesh. PLoS One (2012) 1.19
No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos. Am J Trop Med Hyg (2012) 1.16
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother (2003) 1.16
Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan. Acta Trop (2003) 1.16
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother (2013) 1.15
Severe imported Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2011) 1.15
Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities. Antimicrob Agents Chemother (2003) 1.14
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol (2012) 1.13
Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Mol Biol Evol (2007) 1.13
Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Trop Med Int Health (2005) 1.12
Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med (2005) 1.11
Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis (2008) 1.10
Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol (2008) 1.09
Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene. Am J Trop Med Hyg (2009) 1.09
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res (2008) 1.08
Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis (2012) 1.07
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol (2007) 1.06
PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. Malar J (2013) 1.05
Severe Malaria Not Responsive to Artemisinin Derivatives in Man Returning from Angola to Vietnam. Emerg Infect Dis (2015) 1.02
Chloroquine-resistant malaria in travelers returning from Haiti after 2010 earthquake. Emerg Infect Dis (2012) 1.01
Sensitivity analysis when data are missing not-at-random. Epidemiology (2011) 1.01
Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. Am J Trop Med Hyg (2004) 1.00
Adaptive differentiation of Plasmodium falciparum populations inferred from single-nucleotide polymorphisms (SNPs) conferring drug resistance and from neutral SNPs. J Infect Dis (2010) 1.00
Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. AIDS (2009) 0.99
Molecular epidemiology of malaria in Cameroon. XXIV. Trends of in vitro antimalarial drug responses in Yaounde, Cameroon. Am J Trop Med Hyg (2007) 0.99
Low autochtonous urban malaria in Antananarivo (Madagascar). Malar J (2006) 0.98
Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. Am J Trop Med Hyg (2002) 0.96
Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy. Malar J (2008) 0.96
Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob Agents Chemother (2012) 0.94
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol (2012) 0.94
Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. Emerg Infect Dis (2008) 0.93